Skip to main content
Erschienen in: Infection 6/2017

04.08.2017 | Original Paper

Outcomes of multidrug-resistant tuberculosis in Zambia: a cohort analysis

verfasst von: Nathan Kapata, Martin P. Grobusch, Gershom Chongwe, Pascalina Chanda-Kapata, William Ngosa, Mathias Tembo, Shebba Musonda, Patrick Katemangwe, Matthew Bates, Peter Mwaba, Alimuddin Zumla, Frank Cobelens

Erschienen in: Infection | Ausgabe 6/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The purpose of this study was to establish a baseline for measuring the impact of the programmatic management of drug-resistant TB program by following up on outcomes of all patients diagnosed with multidrug-resistant tuberculosis in Zambia between 2012 and 2014.

Methods

A cohort study of all the MDR-TB patients diagnosed at the national TB reference laboratory from across Zambia. MDR-TB was diagnosed by culture and DST, whereas outcome data were collected in 2015 by patient record checks and home visits.

Results

The total number of patients diagnosed was 258. Of those, 110 (42.6%) patients were traceable for this study. There were 67 survivor participants (60.9%); 43 (39.1%) were deceased. Out of the 110 patients who were traced, only 71 (64.5%) were started on second-line treatment. Twenty-nine (40.8%) patients were declared cured and 16.9% were still on treatment; 8.4% had failed treatment. The survival rate was 20.2 per 100 person-years of follow-up. Taking ARVs was associated with a decreased risk of dying (hazard ratio 0.12, p = 0.002). Sex, age, marital status and treatment category were not important predictors of survival in MDR-TB patients.

Conclusions

More than half of the patients diagnosed with MDR-TB were lost to follow-up before second-line treatment was initiated.
Literatur
1.
Zurück zum Zitat World Health Organization, Global TB Report 2016. Geneva, Switzerland. World Health Organization, Global TB Report 2016. Geneva, Switzerland.
2.
Zurück zum Zitat Gandhi NR, Moll A, Sturm AW, Pawinski R, Govender T, Lalloo U, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet. 2006;368:1575–80.CrossRefPubMed Gandhi NR, Moll A, Sturm AW, Pawinski R, Govender T, Lalloo U, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet. 2006;368:1575–80.CrossRefPubMed
3.
Zurück zum Zitat Shah N, Wright A, Bai GH, Barrera L, Boulahbal F, Martín-Casabona N, et al. Worldwide emergence of extensively drug-resistant tuberculosis (XDR TB): global survey of second-line drug resistance among Mycobacterium tuberculosis isolates. Emerg Infect Dis. 2007;13:380–7.CrossRefPubMedPubMedCentral Shah N, Wright A, Bai GH, Barrera L, Boulahbal F, Martín-Casabona N, et al. Worldwide emergence of extensively drug-resistant tuberculosis (XDR TB): global survey of second-line drug resistance among Mycobacterium tuberculosis isolates. Emerg Infect Dis. 2007;13:380–7.CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Lukoye D, Ssengooba W, Musisi K, Kasule GW, Cobelens FG, Joloba M, et al. Variation and risk factors of drug resistant tuberculosis in sub-Saharan Africa: a systematic review and meta-analysis. BMC Public Health. 2015;25:291. doi:10.1186/s12889-015-1614-8.CrossRef Lukoye D, Ssengooba W, Musisi K, Kasule GW, Cobelens FG, Joloba M, et al. Variation and risk factors of drug resistant tuberculosis in sub-Saharan Africa: a systematic review and meta-analysis. BMC Public Health. 2015;25:291. doi:10.​1186/​s12889-015-1614-8.CrossRef
5.
Zurück zum Zitat Andrews RJ, Shah NS, Gandhi N, Moll T, Friedland G, et al. Multidrug-resistant and extensively drug-resistant tuberculosis: implications for the HIV epidemic and anti-retroviral therapy rollout in South Africa. JID. 2007;196:S482–90.CrossRefPubMed Andrews RJ, Shah NS, Gandhi N, Moll T, Friedland G, et al. Multidrug-resistant and extensively drug-resistant tuberculosis: implications for the HIV epidemic and anti-retroviral therapy rollout in South Africa. JID. 2007;196:S482–90.CrossRefPubMed
6.
Zurück zum Zitat Berhan A, Berhan Y, Yizengaw D. A meta-analysis of drug resistant tuberculosis in Sub Saharan Africa: how strongly associated with previous treatment and HIV co-infection? Ethiop J Health Sci. 2013;23:271–82.PubMedPubMedCentral Berhan A, Berhan Y, Yizengaw D. A meta-analysis of drug resistant tuberculosis in Sub Saharan Africa: how strongly associated with previous treatment and HIV co-infection? Ethiop J Health Sci. 2013;23:271–82.PubMedPubMedCentral
7.
Zurück zum Zitat Kapata N, Chanda-Kapata P, O’Grady J, Schwank S, Bates M, Mukonka V, et al. Trends of Zambia’s tuberculosis burden over the past two decades. Trop Med Int Health. 2011;16:1404–9.CrossRefPubMed Kapata N, Chanda-Kapata P, O’Grady J, Schwank S, Bates M, Mukonka V, et al. Trends of Zambia’s tuberculosis burden over the past two decades. Trop Med Int Health. 2011;16:1404–9.CrossRefPubMed
9.
Zurück zum Zitat MOH. Guidelines for the programmatic management of drug-resistant tuberculosis in Zambia. Lusaka: Ministry of Health; 2015. MOH. Guidelines for the programmatic management of drug-resistant tuberculosis in Zambia. Lusaka: Ministry of Health; 2015.
10.
Zurück zum Zitat Kapata N, Chanda-Kapata P, Bates M, Mwaba P, Cobelens F, Grobusch MP, et al. Multidrug-resistant TB in Zambia: review of national data from 2000 to 2011. Trop Med Int Health. 2013;18:1386–91.CrossRefPubMed Kapata N, Chanda-Kapata P, Bates M, Mwaba P, Cobelens F, Grobusch MP, et al. Multidrug-resistant TB in Zambia: review of national data from 2000 to 2011. Trop Med Int Health. 2013;18:1386–91.CrossRefPubMed
11.
Zurück zum Zitat Kapata N, Mbulo G, Cobelens F, de Haas P, Schaap A, Mwamba P, et al. The Second Zambian National Tuberculosis Drug Resistance survey—a comparison of conventional and molecular methods. Trop Med Int Health. 2015;20:1492–500.CrossRefPubMed Kapata N, Mbulo G, Cobelens F, de Haas P, Schaap A, Mwamba P, et al. The Second Zambian National Tuberculosis Drug Resistance survey—a comparison of conventional and molecular methods. Trop Med Int Health. 2015;20:1492–500.CrossRefPubMed
13.
Zurück zum Zitat Nkosi D, Janssen S, Padanilam X, Louw R, Menezes CN, Grobusch MP. Factors influencing specialist care referral of multidrug- and extensively drug-resistant tuberculosis patients in Gauteng/South Africa: a descriptive questionnaire-based study. BMC Health Serv Res. 2013; 13:268. http://www.biomedcentral.com/1472-6963/13/268. Accessed 10 Jan 2017. Nkosi D, Janssen S, Padanilam X, Louw R, Menezes CN, Grobusch MP. Factors influencing specialist care referral of multidrug- and extensively drug-resistant tuberculosis patients in Gauteng/South Africa: a descriptive questionnaire-based study. BMC Health Serv Res. 2013; 13:268. http://​www.​biomedcentral.​com/​1472-6963/​13/​268. Accessed 10 Jan 2017.
16.
17.
Zurück zum Zitat MacPherson P, Houben MGJR, Glynn RJ, Corbett EL, Kranzer K. Pre-treatment loss to follow-up in tuberculosis patients in low- and lower-middle-income countries and high-burden countries: a systematic review and meta-analysis. Bull World Health Organ. 2014;92:126–38. doi:10.2471/BLT.13.124800.CrossRefPubMed MacPherson P, Houben MGJR, Glynn RJ, Corbett EL, Kranzer K. Pre-treatment loss to follow-up in tuberculosis patients in low- and lower-middle-income countries and high-burden countries: a systematic review and meta-analysis. Bull World Health Organ. 2014;92:126–38. doi:10.​2471/​BLT.​13.​124800.CrossRefPubMed
19.
Zurück zum Zitat Khaliaukin A, Kumar AMV, Skrahina A, Hurevich H, Rusovich V, Gadoev J, et al. Poor treatment outcomes among multidrug-resistant tuberculosis patients in Gomel Region, Republic of Belarus. PHA. 2014;4:S24–8.CrossRefPubMedPubMedCentral Khaliaukin A, Kumar AMV, Skrahina A, Hurevich H, Rusovich V, Gadoev J, et al. Poor treatment outcomes among multidrug-resistant tuberculosis patients in Gomel Region, Republic of Belarus. PHA. 2014;4:S24–8.CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Khann S, Eang MT, Rajendra YP, Satyanarayana S, Nagaraja SB, Kumar AMV. Linkage of presumptive multidrug resistant tuberculosis (MDR-TB) patients to diagnostic and treatment services in Cambodia. PLoS One. 2013;8:e59903.CrossRefPubMedPubMedCentral Khann S, Eang MT, Rajendra YP, Satyanarayana S, Nagaraja SB, Kumar AMV. Linkage of presumptive multidrug resistant tuberculosis (MDR-TB) patients to diagnostic and treatment services in Cambodia. PLoS One. 2013;8:e59903.CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Chadha SS, Sharath BN, Reddy K, Jaju J, Vishnu PH, Rao S, et al. Operational challenges in diagnosing multi-drug resistant TB and initiating treatment in Andhra Pradesh, India. PLos One. 2011;6:e26659.CrossRefPubMedPubMedCentral Chadha SS, Sharath BN, Reddy K, Jaju J, Vishnu PH, Rao S, et al. Operational challenges in diagnosing multi-drug resistant TB and initiating treatment in Andhra Pradesh, India. PLos One. 2011;6:e26659.CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Ade S, Adjibodé O, Wachinou P, Toundoh N, Awanou B, Agodokpessi G, et al. Characteristics and treatment outcomes of retreatment tuberculosis patients in Benin. Tuberc Res Treat. 2016;2016:1468631. doi:10.1155/2016/1468631 (Epub 2016 Mar 24).PubMedPubMedCentral Ade S, Adjibodé O, Wachinou P, Toundoh N, Awanou B, Agodokpessi G, et al. Characteristics and treatment outcomes of retreatment tuberculosis patients in Benin. Tuberc Res Treat. 2016;2016:1468631. doi:10.​1155/​2016/​1468631 (Epub 2016 Mar 24).PubMedPubMedCentral
25.
26.
Zurück zum Zitat Nathavitharana RR, Hillemann D, Schumacher SG, Schlueter B, Ismail N, Omar SV, et al. Multicenter noninferiority evaluation of Hain GenoType MTBDRplus version 2 and Nipro NTMMDRTB line probe assays for detection of rifampin and isoniazid resistance. J Clin Microbiol. 2016;54:1624–30. doi:10.1128/JCM.00251-16.CrossRefPubMedPubMedCentral Nathavitharana RR, Hillemann D, Schumacher SG, Schlueter B, Ismail N, Omar SV, et al. Multicenter noninferiority evaluation of Hain GenoType MTBDRplus version 2 and Nipro NTMMDRTB line probe assays for detection of rifampin and isoniazid resistance. J Clin Microbiol. 2016;54:1624–30. doi:10.​1128/​JCM.​00251-16.CrossRefPubMedPubMedCentral
27.
Zurück zum Zitat Nikolayevskyy V, Balabanova Y, Simak T, Malomanova N, Fedorin I, Drobniewski F, et al. Performance of the Genotype® MTBDRPlus assay in the diagnosis of tuberculosis and drug resistance in Samara, Russian Federation. BMC Clin Pathol. 2009;9:2. doi:10.1186/1472-6890-9-2.CrossRefPubMedPubMedCentral Nikolayevskyy V, Balabanova Y, Simak T, Malomanova N, Fedorin I, Drobniewski F, et al. Performance of the Genotype® MTBDRPlus assay in the diagnosis of tuberculosis and drug resistance in Samara, Russian Federation. BMC Clin Pathol. 2009;9:2. doi:10.​1186/​1472-6890-9-2.CrossRefPubMedPubMedCentral
28.
Zurück zum Zitat Hicks RM, Padayatchi N, Shah NS, Wolf A, Werner L, Sunkari VB, et al. Malnutrition associated with unfavourable outcome and death among South African MDR-TB and HIV co-infected children. Int J Tuberc Lung Dis. 2014;18:1074–83. doi:10.5588/ijtld.14.0231.CrossRefPubMed Hicks RM, Padayatchi N, Shah NS, Wolf A, Werner L, Sunkari VB, et al. Malnutrition associated with unfavourable outcome and death among South African MDR-TB and HIV co-infected children. Int J Tuberc Lung Dis. 2014;18:1074–83. doi:10.​5588/​ijtld.​14.​0231.CrossRefPubMed
29.
31.
Zurück zum Zitat Shean KP, Willcox PA, Siwendu SN, Laserson KF, Gross L, Kammerer S, Wells CD, et al. Treatment outcome and follow-up of multidrug-resistant tuberculosis patients, West Coast/Winelands, South Africa, 1992–2002. Int J Tuberc Lung Dis. 2008;12:1182–9.PubMed Shean KP, Willcox PA, Siwendu SN, Laserson KF, Gross L, Kammerer S, Wells CD, et al. Treatment outcome and follow-up of multidrug-resistant tuberculosis patients, West Coast/Winelands, South Africa, 1992–2002. Int J Tuberc Lung Dis. 2008;12:1182–9.PubMed
32.
Zurück zum Zitat Brust JC, Gandhi NR, Carrara H, Osburn G, Padayatchi N, et al. High treatment failure and default rates for patients with multidrug-resistant tuberculosis in KwaZulu-Natal, South Africa, 2000–2003. Int J Tuberc Lung Dis. 2010;14:413–9.PubMedPubMedCentral Brust JC, Gandhi NR, Carrara H, Osburn G, Padayatchi N, et al. High treatment failure and default rates for patients with multidrug-resistant tuberculosis in KwaZulu-Natal, South Africa, 2000–2003. Int J Tuberc Lung Dis. 2010;14:413–9.PubMedPubMedCentral
33.
Zurück zum Zitat Isaakidis P, Casas EC, Das M, Tseretopoulou X, Ntzani EE, Ford N. Treatment outcomes for HIV and MDR-TB co-infected adults and children: systematic review and meta-analysis. Int J Tuberc Lund Dis. 2015;19:969–78. doi:10.5588/ijtld.15.0123.CrossRef Isaakidis P, Casas EC, Das M, Tseretopoulou X, Ntzani EE, Ford N. Treatment outcomes for HIV and MDR-TB co-infected adults and children: systematic review and meta-analysis. Int J Tuberc Lund Dis. 2015;19:969–78. doi:10.​5588/​ijtld.​15.​0123.CrossRef
35.
Zurück zum Zitat Ahuja SD, Ashkin D, Avendano M, Banerjee R, Bauer M, Bayona JN, et al. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9153 patients. PLos Med. 2012;9:e1001300.CrossRefPubMedPubMedCentral Ahuja SD, Ashkin D, Avendano M, Banerjee R, Bauer M, Bayona JN, et al. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9153 patients. PLos Med. 2012;9:e1001300.CrossRefPubMedPubMedCentral
36.
Zurück zum Zitat Johnston JC, Shahidi NC, Sadatsafavi M, Fitzgerald JM. Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis. PLos One. 2009;4:e6914.CrossRefPubMedPubMedCentral Johnston JC, Shahidi NC, Sadatsafavi M, Fitzgerald JM. Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis. PLos One. 2009;4:e6914.CrossRefPubMedPubMedCentral
41.
Zurück zum Zitat Holtz TH, Lancaster J, Laserson KF, Wells CD, Thorpe L, Weyer K. Risk factors associated with default from multidrug- resistant tuberculosis treatment, South Africa, 1999–2001. Int J Tuberc Lung Dis. 2006;10:649–55.PubMed Holtz TH, Lancaster J, Laserson KF, Wells CD, Thorpe L, Weyer K. Risk factors associated with default from multidrug- resistant tuberculosis treatment, South Africa, 1999–2001. Int J Tuberc Lung Dis. 2006;10:649–55.PubMed
43.
44.
Zurück zum Zitat Huson MA, Kalkman R, Stolp SM, Janssen S, Alabi AS, Beyeme JO, van der Poll T, Grobusch MP. The impact of HIV on presentation and outcome of bacterial sepsis and other causes of acute febrile illness in Gabon. Infection. 2015;43:443–51. doi:10.1007/s15010-015-0753-2 (Epub 2015 Mar 11).CrossRefPubMedPubMedCentral Huson MA, Kalkman R, Stolp SM, Janssen S, Alabi AS, Beyeme JO, van der Poll T, Grobusch MP. The impact of HIV on presentation and outcome of bacterial sepsis and other causes of acute febrile illness in Gabon. Infection. 2015;43:443–51. doi:10.​1007/​s15010-015-0753-2 (Epub 2015 Mar 11).CrossRefPubMedPubMedCentral
Metadaten
Titel
Outcomes of multidrug-resistant tuberculosis in Zambia: a cohort analysis
verfasst von
Nathan Kapata
Martin P. Grobusch
Gershom Chongwe
Pascalina Chanda-Kapata
William Ngosa
Mathias Tembo
Shebba Musonda
Patrick Katemangwe
Matthew Bates
Peter Mwaba
Alimuddin Zumla
Frank Cobelens
Publikationsdatum
04.08.2017
Verlag
Springer Berlin Heidelberg
Erschienen in
Infection / Ausgabe 6/2017
Print ISSN: 0300-8126
Elektronische ISSN: 1439-0973
DOI
https://doi.org/10.1007/s15010-017-1054-8

Weitere Artikel der Ausgabe 6/2017

Infection 6/2017 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.